ContractWarrant Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • New York
THESE WARRANTS AND ANY SHARES ACQUIRED UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. THESE WARRANTS AND SUCH SHARES AND ANY INTEREST OR PARTICIPATION HEREIN OR THEREIN MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS. THESE WARRANTS AND SUCH SHARES MAY NOT BE EXERCISED OR TRANSFERRED EXCEPT UPON THE CONDITIONS SPECIFIED IN THIS WARRANT CERTIFICATE, AND NO EXERCISE OR TRANSFER OF THESE WARRANTS OR TRANSFER OF SUCH SHARES SHALL BE VALID OR EFFECTIVE UNLESS AND UNTIL SUCH CONDITIONS SHALL HAVE BEEN COMPLIED WITH.
EMPLOYMENT AGREEMENTEmployment Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • California
This Employment Agreement (this “Agreement”) is entered into as of ___________, 2022 by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and Matthew K. Szot (“Executive”). Together, Executive and the Company are sometimes referred to as the “Parties.” Capitalized terms not otherwise defined herein shall have the meanings set forth in Section 9 below.
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations
THIS PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is dated as of April 1 , 2022 (“Effective Date”), and is made by and between HESP LLC, a Delaware limited liability company (“Assignor”), and Cadrenal Therapeutics Inc., a Delaware corporation (“Assignee”). Each of Assignor and Assignee may be referenced herein as a “Party,” and collectively, the “Parties.”
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”), dated as of April 1 , 2022, by and between HESP LLC, a Delaware limited liability company (“Seller”) and Cadrenal Therapeutics Inc., a Delaware corporation (“Purchaser”). Article 8 contains definitions of certain capitalized terms used herein and also provides cross-references to certain capitalized terms defined elsewhere in this Agreement.
INVESTOR RIGHTS AND LOCK-UP AGREEMENTInvestor Rights and Lock-Up Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • California
This INVESTOR RIGHTS AND LOCK-UP AGREEMENT (this “Agreement”) is made and entered into as of ____________ ____, 2022 by and among Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and the investor on the signature page hereto.
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations
This Amendment to the Asset Purchase Agreement (“Amendment”), dated August 18, 2022, is entered into by and between HESP LLC, a Delaware limited liability company (“Seller”) and Cadrenal Therapeutics, Inc., a Delaware corporation (“Purchaser”).
SUBSCRIPTION AGREEMENTSubscription Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • Delaware
CONSULTING AGREEMENTConsulting Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) is made and entered into as of May 17, 2022 (the “Effective Date”) by and between Cadrenal Therapeutics, Inc., a Delaware corporation with its principal place of business at 822 A1A North, Suite 320, Ponte Vedra, Florida 32082 (the “Company”), and Matthew Szot, an individual residing at Carlsbad, CA (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).
January 25, 2022 Quang Pham President Cadrenal Therapeutics, Inc.Consulting Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations
RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Pursuant to the terms of this Restricted Stock Purchase Agreement (the “Agreement”), Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), has issued to Matthew Szot (the “Holder”) 450,000 shares of restricted common stock of the Company, par value $0.001 (“Common Stock”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • Florida
This EMPLOYMENT AGREEMENT (this “Agreement”), dated March 1, 2022, effective as of the Effective Time (the “Effective Date”), is by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and Quang Pham (the “Executive”).
CADRENAL THERAPEUTICS, INC. CONVERTIBLE NOTEConvertible Note • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • New York
FOR VALUE RECEIVED, Cadrenal Therapeutics, Inc., a Delaware corporation (“Cadrenal Therapeutics” or the “Maker”), hereby promises to pay to the order of _________________________ (the “Subscriber”), or registered assigns (together with the Subscriber, the “Holder”), the amount set out above as the Original Principal Amount, as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise (the “Principal”), when due, whether upon the Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest (“Interest”) on any outstanding Principal at the applicable Interest Rate from the date set out above as the Issuance Date (the “Issuance Date”) until the same becomes due and payable, upon the Maturity Date or acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof).
